Table 2 Patient and donor characteristics in the prospective study

Number of patients

340

62

20

202

56

Median age (range), years

32 (3–65)

39 (4–55)

41.5 (7–62)

0.612

30 (3–65)

26 (4–61)

0.151

Weight (range), kg

62 (15.5–140)

63 (15.5–91)

65.25 (28–95)

0.631

62 (17–140)

58 (19–92)

0.090

Male, n (%)

208 (61.2%)

32 (51.6%)

15 (75.0%)

0.066

127 (62.9%)

34 (60.7%)

0.768

Diagnosis, n (%)

0.146

0.603

 De novo AML

318 (93.5%)

61 (98.4%)

18 (90.0%)

187 (92.6%)

52 (92.9%)

 Secondary AML

22 (6.5%)

1 (1.6%)

2 (10.0%)

15 (7.4%)

4 (7.1%)

Disease status, n (%)

0.165

 CR1

293 (86.2%)

56 (90.3%)

15 (75.0%)

0.080

177 (87.6%)

45 (80.4%)

 CR > 1

47 (13.8%)

6 (9.7%)

5 (25.0%)

25 (12.4%)

11 (19.6%)

FLT3-ITD mutation

0.390

0.610

 Yes

49 (14.4%)

11 (17.7%)

2 (10.0%)

27 (13.4%)

9 (16.1%)

 No

291 (85.6%)

51 (82.3%)

18 (90.0%)

175 (86.6%)

47 (83.9%)

Cytogenetics

0.500

0.277

 Favorable

43 (12.6%)

7 (11.3%)

1 (5.0%)

28 (13.9%)

7 (12.5%)

 Intermediate

263 (77.4%)

50 (80.6%)

16 (80.0%)

157 (77.7%)

40 (71.4%)

 Adverse

34 (10.0%)

5 (8.1%)

3 (15.0%)

17 (8.4%)

9 (16.1%)

 MA

340 (100%)

62 (100%)

20 (100%)

202 (100%)

56 (100%)

HLA-A-, B-, and DR-mismatched grafts, n (%)

0.599

 0

84 (24.7%)

62 (100%)

20 (100%)

2 (1.0%)

0

 1

7 (2.1%)

0

0

5 (2.5%)

2 (3.6%)

 2

31 (9.1%)

0

0

22 (10.9%)

9 (16.1%)

 3

218 (64.1%)

0

0

173 (85.6%)

45 (80.4%)

 Male–male

136 (40.0%)

15 (24.2%)

6 (30.0%)

94 (46.5%)

21 (37.5%)

 Male–female

86 (25.3%)

14 (22.6%)

3 (15.0%)

55 (27.2%)

14 (25.0%)

 Female–male

75 (22.1%)

18 (29.0%)

2 (10.0%)

33 (16.3%)

15 (26.8%)

 Female–female

43 (12.6%)

15 (24.2%)

9 (45.0%)

20 (9.9%)

6 (10.7%)

Donor-recipient relationship, n (%)

0.283

 Parent–child

132 (38.8%)

0

0

99 (49.0%)

33 (58.9%)

 Sibling–sibling

153 (45.0%)

62 (100%)

20 (100%)

61 (30.2%)

10 (17.9%)

 Child–parent

49 (14.4%)

0

0

37 (18.3%)

12 (21.4%)

 Other

6 (1.8%)

0

0

5 (2.5%)

1 (1.8%)

ABO matched grafts, n (%)

0.344

 Matched

179 (52.6%)

40 (64.5%)

14 (70.0%)

0.660

97 (48.0%)

28 (50.0%)

 Major mismatch

70 (20.6%)

10 (16.1%)

4 (20.0%)

45 (22.3%)

11 (19.6%)

 Minor mismatch

72 (21.2%)

8 (12.9%)

2 (10.0%)

46 (22.8%)

16 (28.6%)

 Bi-directional mismatch

19 (5.6%)

4 (6.5%)

0

14 (6.9%)

1 (1.8%)

EBMT score, n (%)

0.125

0.546

 0

2 (0.6%)

1 (1.6%)

1 (5.0%)

0

0

 1

66 (19.4%)

21 (33.9%)

6 (30.0%)

31 (15.3%)

8 (14.3%)

 2

145 (42.6%)

28 (45.2%)

6 (30.0%)

90 (44.6%)

21 (37.5%)

 3

91 (26.8%)

11 (17.7%)

4 (20.0%)

58 (28.7%)

18 (32.1%)

 4

30 (8.8%)

1 (1.6%)

3 (15.0%)

20 (9.9%)

6 (10.7%)

 5

6 (1.8%)

0

0

3 (1.5%)

3 (5.4%)

 Infused nuclear cells, (range) 10⁸/kg

7.83 (2.27–16.66)

7.59 (5.18–14.93) (5.18–14.93)

7.22 (2.27–9.29)

0.201

7.88 (3.93–15.97)

8.17 (3.44–16.66)

0.517

 Infused CD34⁺ cells, (range) 10⁶/kg

2.55 (0.22–10.95)

2.53 (0.41–6.43)

2.65 (0.90–5.47)

0.829

2.49 (0.22–10.95)

2.78 (0.38–7.20)

0.340

 For relapse prophylaxis and intervention

32 (9.4%)

5 (8.1%)

4 (20.0%)

0.211

8 (4.0%)

14 (25.0%)

<0.001

 For relapse treatment

8 (2.4%)

2 (3.2%)

2 (10.0%)

0.249

3 (1.5%)

2 (3.6%)

0.297